Co-Stimulation of Adaptive and Innate Immune Cells to Achieve Clinical Benefit with MDNA11, a Long-Acting ‘Beta-only’ IL-2 Super-Agonist

Time: 1:00 pm


  • MDNA11 is an albumin fusion to a variant of IL-2 bestowed with enhanced affinity for CD122 and deprived of CD25 binding, with the intent to selectively stimulate immune effector cells. The presentation will comprise:
  • Preliminary results from the ongoing MDNA11 Phase 1/2 ABILITY Clinical Trial in patients with advanced solid tumors
  • Emerging safety and clinical benefit as we establish the recommended phase 2 dose (RP2D) and schedule during monotherapy dose-escalation, and
  • Compare the PK profile and PD response of MDNA11 within the IL-2 class of immuno-therapies for oncology